Managing and Preventing Hypofibrinogenemia in Pediatric and AYA Leukemia Patients: Insights From MD Anderson Cancer Center
Cryoprecipitate is commonly administered to children with leukemia, effectively raising fibrinogen levels with minimal associated side effects. However, further research, ideally through randomized trials, is needed to assess its true clinical benefits in this population. Currently, there is a notable lack of pediatric-focused randomized transfusion medicine trials. Integrating these studies into ongoing oncologic trials could be a practical and valuable approach that warrants careful consideration and planning.
Authors
- Samanta Catueno (ORCID: https://orcid.org/0000-0002-0072-8603)
- Michael Roth (ORCID: https://orcid.org/0000-0002-6411-8353)
- Camila Ayerbe
- Nidra Rodriguez
- Priti Tewari
- Miriam B. Garcia (ORCID: https://orcid.org/0000-0002-2978-2267)
- José R. Cortés (ORCID: https://orcid.org/0000-0002-4457-3850)
- Branko Cuglievan (ORCID: https://orcid.org/0000-0002-6917-2244)
- David McCall (ORCID: https://orcid.org/0000-0003-2297-9670)
- Jiasen He (ORCID: https://orcid.org/0000-0001-7479-4315)
- Amber Gibson (ORCID: https://orcid.org/0000-0002-9146-4702)
- Faryal Munir (ORCID: https://orcid.org/0000-0002-1418-7377)
- César Núnêz (ORCID: https://orcid.org/0000-0002-9701-8826)
- Samantha Dickson
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Journal of Pediatric Hematology/Oncology
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1097/mph.0000000000003042
- Primary Topic
- Blood properties and coagulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00